TOP TEN perturbations for 1183_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1183_at
Selected probe(set): 207900_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1183_at (207900_at) across 6593 perturbations tested by GENEVESTIGATOR:

dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)

Relative Expression (log2-ratio):8.593872
Number of Samples:3 / 3
Experimental dendritic cell study 7 (IL-4 mddc)
Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.
Control dendritic cell study 7 (IL-15 mddc)
Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.

IL-4; antiCD40 study 1 / normal resting B-cell sample

Relative Expression (log2-ratio):6.810173
Number of Samples:2 / 2
Experimental IL-4; antiCD40 study 1
B-cells antiCD40/IL-4 activated for 30h.
Control normal resting B-cell sample
B cells resting for 30h.

B-cell activation study 1 / unstimulated B-cell sample

Relative Expression (log2-ratio):5.9456825
Number of Samples:4 / 4
Experimental B-cell activation study 1
Tonsillar B-cell samples stimulated with 10 µg/mL anti-CD40 antibody and 100 U/mL recombinant human IL-4. Cells were cultured under TH2-skewing conditions for 24 hours.
Control unstimulated B-cell sample
Unstimulated tonsillar B-cells cultured for 24 hours.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):5.633519
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):5.0923634
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)

Relative Expression (log2-ratio):-3.9858809
Number of Samples:6 / 10
Experimental diphenylcyclopropenone study 1 (late)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:---
Control diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---

galectin-1 study 1 / vehicle (DTT/polym. B) treated monocyte sample

Relative Expression (log2-ratio):3.4642057
Number of Samples:3 / 3
Experimental galectin-1 study 1
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, galectin-1 (20 μM) in the presence of 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.
Control vehicle (DTT/polym. B) treated monocyte sample
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):3.4451704
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

diphenylcyclopropenone study 1 (early) / placebo treated skin tissue

Relative Expression (log2-ratio):3.3614922
Number of Samples:10 / 11
Experimental diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---
Control placebo treated skin tissue
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):3.3292675
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.